Tolcapone improves outcomes in patients with Parkinson disease treated by levodopa/carbidopa intestinal gel: A pilot study

BACKGROUND: Patients with Parkinson disease (PD) treated with levodopa/carbidopa intestinal gel (LCIG) have higher prevalence of hyperhomocysteinemia and peripheral nerves damage. OBJECTIVE: The aim of our study was to test the effect of catechol-O-methyl transferase inhibitor tolcapone—as an add-on...

Descripción completa

Detalles Bibliográficos
Autores principales: Valkovič, Peter, Minár, Michal, Matejička, Peter, Gmitterová, Karin, Boleková, Veronika, Košutzká, Zuzana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371526/
https://www.ncbi.nlm.nih.gov/pubmed/35960120
http://dx.doi.org/10.1097/MD.0000000000029526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371526/
https://www.ncbi.nlm.nih.gov/pubmed/35960120
http://dx.doi.org/10.1097/MD.0000000000029526

Ejemplares similares